Revance Therapeutics, Inc. Quarterly Research and Development Expense in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Revance Therapeutics, Inc. quarterly/annual Research and Development Expense history and growth rate from Q1 2013 to Q3 2024.
  • Revance Therapeutics, Inc. Research and Development Expense for the quarter ending September 30, 2024 was $11.4M, a 31% increase year-over-year.
  • Revance Therapeutics, Inc. Research and Development Expense for the twelve months ending September 30, 2024 was $77.2M, a 21.9% increase year-over-year.
  • Revance Therapeutics, Inc. annual Research and Development Expense for 2023 was $79.4M, a 21.6% decline from 2022.
  • Revance Therapeutics, Inc. annual Research and Development Expense for 2022 was $101M, a 12.9% decline from 2021.
  • Revance Therapeutics, Inc. annual Research and Development Expense for 2021 was $116M, a 7.58% decline from 2020.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $77.2M $11.4M +$2.69M +31% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $74.5M $15.9M -$1.72M -9.77% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $76.3M $14.4M -$3.14M -17.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $79.4M $35.6M +$16M +82% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $63.4M $8.69M -$17.4M -66.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $80.8M $17.6M -$7.29M -29.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $88.1M $17.5M -$13.2M -42.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $101M $19.5M -$9.93M -33.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $111M $26.1M -$3.99M -13.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $115M $24.9M -$4.53M -15.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $120M $30.7M +$3.48M +12.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $116M $29.5M -$300K -1.01% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $117M $30.1M +$965K +3.31% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $116M $29.4M +$2.34M +8.63% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $113M $27.3M -$12.5M -31.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $126M $29.8M +$2.28M +8.28% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $124M $29.1M +$3.28M +12.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $120M $27.1M +$1.58M +6.18% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $119M $39.8M +$15.8M +65.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $103M $27.5M +$1.95M +7.64% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $101M $25.8M +$4M +18.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $96.9M $25.5M +$2.66M +11.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $94.3M $24M +$1.76M +7.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $92.5M $25.5M +$4.54M +21.6% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $88M $21.8M +$205K +0.95% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 $87.8M $22.9M +$4.56M +24.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $83.2M $22.2M +$2.83M +14.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $80.4M $21M +$8.47M +67.6% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 $71.9M $21.6M +$11.3M +110% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 $60.5M $18.3M +$3.12M +20.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 $57.4M $19.4M +$7.05M +57% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $50.4M $12.5M -$2.43M -16.2% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $52.8M $10.3M -$2.72M -20.9% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-03
Q2 2016 $42.3M $15.2M +$4.89M +47.5% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-04
Q2 2016 $2M -$8.3M -80.6% Jun 2, 2016 10-K 2019-02-28
Q1 2016 $50.6M $12.4M +$3.11M +33.6% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $47.5M $15M +$5.83M +63.8% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-02
Q3 2015 $41.7M $13M +$4.42M +51.3% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 $37.3M $10.3M +$2.19M +27% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-05
Q1 2015 $35.1M $9.25M +$1.7M +22.6% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 $33.4M $9.13M +$2.89M +46.3% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-28
Q3 2014 $30.5M $8.6M +$2.32M +36.9% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-10
Q2 2014 $28.2M $8.11M +$328K +4.22% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 $27.9M $7.55M +$24K +0.32% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-14
Q4 2013 $27.8M $6.24M Oct 1, 2013 Dec 31, 2013 10-K 2016-03-04
Q3 2013 $6.28M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
Q2 2013 $7.78M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-13
Q1 2013 $7.53M Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.